HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David R. Jones Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Denlinger, C. E. Articles by Jones, D. R. Search for Related Content PubMed PubMed Citation Articles by Denlinger, C. E. Articles by Jones, D. R. Related Collections Lung - cancer Molecular biology

J Thorac Cardiovasc Surg 2005;130:1422-1429
© 2005 The American Association for Thoracic Surgery

General Thoracic Surgery

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

Department of Surgery, University of Virginia, Charlottesville, Va

Read at the Eighty-fifth Annual Meeting of The American Association for Thoracic Surgery, San Francisco, Calif, April 10-13, 2005.

Received for publication April 10, 2005; revisions received June 6, 2005; accepted for publication June 16, 2005.

^_* Address for reprints: David R. Jones, MD, Department of Surgery, Box 800679, University of Virginia, Charlottesville, VA 22908-0679 (Email: djones{at}virginia.edu).

OBJECTIVE: Resistance to histone deacetylase inhibitors in non–small cell lung cancer is mediated in part through activation of nuclear factor-B through a phosphatidylinositol 3-kinase/Akt–dependent pathway. We hypothesize that inhibition of phosphatidylinositol 3-kinase/Akt will sensitize non–small cell lung cancer cells to histone deacetylase inhibitor-induced apoptosis.

METHODS: Tumorigenic non–small cell lung cancer cell lines H157, H358, H460, and A549 were treated with nothing, the histone deacetylase inhibitor butyrate, the phosphatidylinositol 3-kinase/Akt inhibitor LY294002, or both compounds. Nuclear factor-B activity was assessed by reporter gene assays and reverse transcriptase-polymerase chain reaction of the nuclear factor-B dependent genes cIAP-2, Bfl/A1, and MnSOD. Whole cell extracts were immunoblotted for phospho-Akt, Akt, and phospho-ser/thr-Akt substrate. Cell death and apoptosis were measured by crystal violet staining, caspase-3 activity, and DNA fragmentation. A549 non–small cell lung cancer xenografts were created in athymic nude mice, and tumor growth was assessed after treatments as noted above. Explanted tumors underwent terminal deoxynucleotide transferase-mediated dUTP nick-end labeling and Western blot analyses for apoptosis assessment and drug target validation, respectively.

RESULTS: Butyrate activated nuclear factor-B–dependent transcription, and LY294002 abrogated this effect. Combined treatment induced more apoptosis and cell death in vitro compared with either drug alone as measured by caspase-3, DNA fragmentation, and clonogenic survival. Combined butyrate and LY294002 was tumoristatic in vivo, but all other xenografts grew. This decreased tumor growth correlated with more apoptosis in the xenografts treated with combined therapy. Tumor levels of phospho-Akt and acetylated histone H3 were decreased and increased, respectively, in xenografts treated with combined therapy.

CONCLUSIONS: Combined histone deacetylase inhibitor and phosphatidylinositol 3-kinase/Akt pathway inhibition sensitized non–small cell lung cancer xenografts to apoptosis. Further investigations of this combined therapy are warranted as new pharmacologic phosphatidylinositol 3-kinase/Akt pathway inhibitors are developed.

This article has been cited by other articles:

				X. Xu, A. Muller-Taubenberger, K. E. Adley, N. Pawolleck, V. W. Y. Lee, C. Wiedemann, T. S. Sihra, M. Maniak, T. Jin, and R. S. B. Williams Attenuation of Phospholipid Signaling Provides a Novel Mechanism for the Action of Valproic Acid Eukaryot. Cell, June 1, 2007; 6(6): 899 - 906. [Abstract] [Full Text] [PDF]

				C. Yu, B. B. Friday, J.-P. Lai, A. McCollum, P. Atadja, L. R. Roberts, and A. A. Adjei Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation Clin. Cancer Res., February 15, 2007; 13(4): 1140 - 1148. [Abstract] [Full Text] [PDF]

				J. Duan, J. Friedman, L. Nottingham, Z. Chen, G. Ara, and C. Van Waes Nuclear factor-{kappa}B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther., January 1, 2007; 6(1): 37 - 50. [Abstract] [Full Text] [PDF]

				L. Y. Sun and A. J. D'Ercole Insulin-Like Growth Factor-I Stimulates Histone H3 and H4 Acetylation in the Brain in Vivo Endocrinology, November 1, 2006; 147(11): 5480 - 5490. [Abstract] [Full Text] [PDF]

				Y. Liu, C. E. Denlinger, B. K. Rundall, P. W. Smith, and D. R. Jones Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65 J. Biol. Chem., October 20, 2006; 281(42): 31359 - 31368. [Abstract] [Full Text] [PDF]